Pfizer CEO Albert Bourla mentioned Tuesday the corporate has been contracted to ship 1.6 billion doses of its Covid-19 vaccine globally this year, and the corporate expects to supply no less than 3 billion doses of the vaccine in 2022. The firm is in discussions with international locations for multi-year contracts of potential provide.
Bourla mentioned the corporate is anticipating roughly $26 billion in income from its Covid-19 vaccine in 2021.
Pfizer says it’s not but clear how lengthy the vaccine will defend in opposition to Covid-19, however Bourla mentioned demand for the vaccine is predicted to stay excessive. “Based on what we’ve seen, we believe that a durable demand for our COVID-19 vaccine – similar to that of the flu vaccines – is a likely outcome,” Bourla mentioned.
In addition to testing a 3rd dose as a booster in opposition to variants, Bourla mentioned, Pfizer can be engaged on a model of the vaccine that particularly targets the B.1351 variant, which was first recognized in South Africa. According to Bourla, efficacy information for each the booster and the B.1351 particular vaccine can be out there in early July. He famous that the research design of the B.1351 variant vaccine would probably be a prototype in order that Pfizer might replace it to focus on new variants of concern in roughly 100 days.
Bourla additionally mentioned the corporate was engaged on trialing two antiviral remedies to deal with Covid-19, one administered as a shot and the opposite orally. The firm expects to start section 2/3 trials of these remedies this summer time and anticipates making use of for approvals by the tip of the year. The remedies will be examined for his or her efficacy in treating Covid-19 and will be evaluated in opposition to the present monoclonal antibody therapy for Covid-19. They will even be examined as a possible prophylaxis, testing in unvaccinated households that have a Covid-19 an infection to see if it prevents further infections.